Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prazosin Hydrochloride

FDA-approved product (capsule, oral), marketed as Minipress, Minipress Xl, Prazosin Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Prazosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prazosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prazosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Japan Morning Surge-1 Study

    NCT00285519 · start 2003-08

    Registered record
    Registry ID
    NCT00285519
    Conditions
    Hypertension
    Interventions
    Doxazosin (drug)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-08
    Completion
    2005-08
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionDoxazosin (drug)
    PhasePhase 4
    Registry statusCompleted

  • Alzheimer's in Long-Term Care--Treatment for Agitation

    NCT00161473 · start 2001-01

    Registered record
    Registry ID
    NCT00161473
    Conditions
    Alzheimer Disease; Psychomotor Agitation
    Interventions
    prazosin; placebo (inert substance)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2001-01
    Completion
    2009-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Psychomotor Agitation
    Interventionprazosin; placebo (inert substance)
    PhaseNot applicable
    Registry statusCompleted

  • Treatment of Supine Hypertension in Autonomic Failure

    NCT00223717 · start 2001-01

    Registered record
    Registry ID
    NCT00223717
    Conditions
    Hypertension
    Interventions
    Clonidine; Nitroglycerin transdermal; Dipyridamole/ Aspirin (Aggrenox); Desmopressin (DDAVP); Sildenafil; Nifedipine; Hydralazine; Hydrochlorothiazide; Placebo; Bosentan; Diltiazem; Eplerenone; guanfacine; L-arginine; captopril; carbidopa; losartan; metoprolol tartrate; nebivolol hydrochloride; prazosin hydrochloride; tamsulosin hydrochloride; Head-up tilt.; aliskiren; Local heat stress
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-01
    Completion
    2017-01
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionClonidine; Nitroglycerin transdermal; Dipyridamole/ Aspirin (Aggrenox); Desmopressin (DDAVP) +20 more
    PhasePhase 1
    Registry statusCompleted

  • Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy

    NCT00295542 · start 2000-03

    Registered record
    Registry ID
    NCT00295542
    Conditions
    Hypertension
    Interventions
    Ambulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan); beta blockers (including nebivolol, atenolol, carvedilol); diuretics (torasemide, indapamide, HTCZ) and doxazosin; Combination therapy in essential hypertension
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-03
    Completion
    2009-04
    Enrolment
    3,344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmbulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) +3 more
    PhasePhase 4
    Registry statusCompleted

  • Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

    NCT00000542 · start 1993-08

    Registered record
    Registry ID
    NCT00000542
    Conditions
    Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Heart Diseases; Hypercholesterolemia; Hypertension; Myocardial Infarction; Myocardial Ischemia; Heart Failure
    Interventions
    Inhibitors, ACE; amlodipine; lisinopril; doxazosin; chlorthalidone; pravastatin; diet, fat-restricted
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1993-08
    Completion
    2002-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Heart Diseases +5 more
    InterventionInhibitors, ACE; amlodipine; lisinopril; doxazosin +3 more
    PhasePhase 3
    Registry statusCompleted